FDA sets August decision date for Provention’s type 1 diabetes drug

[cafead]

via Shares in Provention Bio cratered last July when the FDA turned down its marketing application for type 1 diabetes therapy teplizumab. But armed with new data it has tried again, with the FDA due to make a decision on the new filing by 17 August.

article source